newsfilter
← Latest News
GlobeNewswire·

Myovant Sciences Announces Corporate Updates and Financial Results for Third Fiscal Quarter 2022

Third fiscal quarter 2022 total revenue of $100.2 million; including net product revenue of $61.4 millionNet product revenue from U.S. sales of ORGOVYX® of $48.7 million in third fiscal quarter 2022, with sequential